Evergreen Therapeutics

Evergreen Therapeutics is a leading international innovative pharmaceutical company that leverages AI to empower clinical research and development. Established in 2019, the company has branches in Shenzhen, China, and Maryland, USA, and boasts a multidisciplinary team of top talents in clinical medicine, computational science, chemistry, pharmacology, and FDA regulatory affairs. The company focuses on discovering innovative drugs in the fields of immunology and ophthalmology, as well as conducting efficient clinical development and commercialization globally. Evergreen Therapeutics avoids homogenized trends and adheres to the R&D philosophy of differentiation, efficient clinical trials, and internationalization. By utilizing its unique end-to-end AI technology platform, the company completes the full process of drug development, including new molecule synthesis and optimization, pharmacological and toxicological predictions, indication expansion, and clinical trial implementation. It became the first domestic innovative pharmaceutical enterprise to conduct AI-driven drug R&D using a "dry-wet combination" approach, achieving efficient transformation of R&D results. Currently, the company owns multiple self-developed pipelines and has filed over 50 patent applications. Several candidate drugs have entered the mid-to-late stages of clinical trials, with patents covering major pharmaceutical markets worldwide, including China, the United States, Europe, and Japan. In the future, the company will continue its mission of "addressing urgent needs, promoting efficient clinical practices, and benefiting patients globally," employing end-to-end AI technology to develop groundbreaking (First in Disease) drugs through original innovation, significantly improving the efficiency and success rate of drug R&D, and becoming the most valuable company in the field of AI-powered clinical pharmaceuticals.